Consumer epigenomics and biological age editing: ethical, legal, and social implications

Direct-to-consumer epigenetic testing (DTC-ET) companies are commercializing biological age estimation tests based on DNA methylation patterns, often paired with lifestyle advice or supplements marketed as capable of slowing or reversing aging. While these developments are distinct from epigenomic editing technologies, they similarly seek to reprogram biological processes at the molecular level and raise ethical, legal, and social issues (ELSI), for instance, by blurring further the boundaries between scientific, medical, and commercial interests. As these technologies diffuse rapidly into consumer markets despite ongoing scientific uncertainties, there is an urgent need to understand how experts assess their reliability and practical value, and to anticipate the broader societal impacts of their commercialization. This article presents findings from a real-time Delphi consultation involving relevant experts from the Francophone research community of France and Canada. The panel assessed 13 structured items spanning scientific, ethical, legal, and societal aspects of DTC-ET, and provided qualitative comments. Responses were analyzed using Wienroth’s RULE framework, which evaluates emerging technologies in terms of Reliability, Utility, and LEgitimacy. Results revealed a climate of general concern. No formal consensus was reached on any specific item. Strong disagreement emerged regarding the scientific justification for marketing supplements alongside epigenetic aging tests, with most participants rejecting claims of causal efficacy. Views diverged on the clinical utility of knowing one’s biological age. Privacy and data governance were highlighted as critical issues, with calls for legislation to prevent epigenetic discrimination approaching consensus. Societal concerns included the reinforcement of health inequities due to high test costs, the promotion of “epigenetic youth” narratives that risk entrenching ageism, and the shifting of responsibility for aging from structural conditions to individuals. Our findings suggest that while DTC-ET may hold perceived value for consumers, their scientific and clinical reliability remains limited, their utility contested, and their legitimacy deeply tied to questions of equity, responsibility, and societal perception of aging. As these technologies proliferate, regulators must clarify applicable frameworks, ensure robust protections against misuse of epigenetic data, and address the socio-cultural impacts of commodifying biological youth. Broader interdisciplinary dialogue is needed to anticipate how consumer epigenomics will reshape our collective understanding of aging and epigenetic responsibility.